This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Pharmaceuticals has experienced a 50% stock surge over the past three months, fueled by robust second-quarter results that significantly surpassed analyst expectations, reporting $3.28 EPS and $101.7 million in revenue. The biotech firm also raised its full-year revenue guidance to $270-$280 million, citing strong performance from its existing hematology and oncology treatments. Further growth is anticipated from its pipeline, including a partnered autoimmune drug with Eli Lilly and an early-stage blood cancer treatment (R289) for which initial clinical data is expected in December.

Analysis

Rigel Pharmaceuticals (RIGL) has demonstrated significant operational outperformance, with its stock surging approximately 50% over the last three months. This strong market reaction follows a robust second-quarter earnings report, where the company significantly exceeded analyst expectations, reporting earnings per share of $3.28 against a $2.58 consensus and revenue of $101.7 million, well above the $88.9 million estimate.

The company further solidified its positive outlook by raising its full-year revenue guidance to a range of $270 million to $280 million, a substantial increase from the prior forecast of $200 million to $210 million. CEO Raul Rodriguez highlighted consistent growth, averaging 30% for four years and accelerating to 50% this year, driven by strong performance from existing products like Tavalisse, Gavreto, and Rezlidhia.

Beyond current sales, Rigel's pipeline presents future growth catalysts, including a partnership with Eli Lilly for Ocadusertib, an autoimmune treatment. Additionally, its proprietary R289 for lower-risk myelodysplastic syndrome (LR-MDS) is progressing through early clinical trials, with initial data anticipated at the American Society of Hematology meeting in December, potentially expanding its market opportunity.

Key Decisions for Investors

• Investors should evaluate Rigel's strong financial performance, including its significant Q2 earnings beat and substantially raised full-year revenue guidance, as indicators of robust operational momentum.
• Monitor the progress of Rigel's clinical pipeline, particularly the anticipated R289 data presentation in December, which could serve as a significant catalyst for future valuation.
• Pay close attention to the upcoming Q3 earnings announcement on November 4th for further confirmation of sustained growth and execution against the elevated guidance.